Pulmonary Hypertension

Clinical Trials

Below is a list of Pulmonary Hypertension clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

ACT-293987 in Pulmonary Arterial Hypertension
The AC-065A302 GRIPHON study is an event-driven Phase 3 study to demonstrate the effect of ACT-293987 on time to first clinical worsening in patients with pulmonary arterial hypertension.
Read more

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
The purpose of this multi-center, open-label, safety and tolerability study is to assess the addition of UT-15C SR to patients currently receiving Tyvaso (treprostinil) inhalation solution. The study will consist of a 24-week evaluation period followed by a long-term safety follow up.
Read more

Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging has emerged as a potential valuable test for the early detection of Pulmonary Arterial Hypertension. A number of reports have provided some preliminary evidence that Pulmonary Artery (PA) stiffness may be accurately detected by imaging of the pulmonary artery in order to measure PA stiffness.
Read more

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
This study will investigate the effects of the combination of bosentan and sildenafil. Patients with symptomatic PAH treated with a stable dose of sildenafil equal to or greater tha 20 mg t.i.d.
Read more

Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension PAH Disease Management
This study is being done to better understand the medical management of patients with a new or existing diagnosis of PAH. Other objectives include describing the demographic and clinical characteristics of PAH patients as well as identifying medical practices associated with improved health outcomes.
Read more

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
A post marketing surveillance to determine the type and incidence of oro/nasopharyngeal or pulmonary adverse events that may occur in patients treated with commercially available Tyvaso®(treprostinil) Inhalation Solution. A comparison will be made to the type and incidence of events in patients receiving other FDA approved therapies for pulmonary arterial hypertension, as a control measure.
Read more

Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcomes
The main purpose of this clinical research is to find out if this investigational medication (ACT-064992) can delay the time to clinical worsening of your condition. In other words, this investigational medication might improve your health by: -- Improving the symptoms you experience from your disease -- Increasing your ability to exercise -- Improving your pulmonary artery pressure -- Preventing your disease from worsening
Read more